<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Silodosin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06207</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Silodosin is an &#945;1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. <span class="caps">FDA</span> approved Oct 9, 2008.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06207/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06207/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06207.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06207.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06207.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06207.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06207.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06207">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>KAD 3213</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>KMD 3213 </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Rapaflo</td><td>Watson Pharmaceuticals Inc.</td></tr><tr><td>Rapilif</td><td>Ipca Urosciences </td></tr><tr><td>Silodyx </td><td>Recordati Industria Chimica e Farmaceutica S.p.A.</td></tr><tr><td>Urief</td><td>Watson Pharmaceuticals Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/adrenergic-alpha-1-receptor-antagonists">Adrenergic alpha-1 Receptor Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>160970-54-7</td></tr><tr><th>Weight</th><td>Average: 495.5345<br>Monoisotopic: 495.234491142</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>32</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>PNCPYILNMDWPEY-QGZVFWFLSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Indolecarboxylic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Indolecarboxamides and Derivatives</td></tr><tr><th>Alternative parents</th><td>Amphetamines and Derivatives; Benzamides; Phenol Ethers; Benzoyl Derivatives; Alkyl Aryl Ethers; Tertiary Amines; Polyols; Primary Carboxylic Acid Amides; Enolates; Carboxylic Acids; Dialkylamines; Polyamines; Primary Alcohols; Alkyl Fluorides; Organofluorides</td></tr><tr><th>Substituents</th><td>amphetamine or derivative; benzamide; phenol ether; benzoyl; alkyl aryl ether; benzene; carboxamide group; primary carboxylic acid amide; polyol; tertiary amine; primary alcohol; secondary amine; enolate; polyamine; secondary aliphatic amine; carboxylic acid derivative; ether; carboxylic acid; organohalogen; organofluoride; amine; alcohol; alkyl halide; alkyl fluoride; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment for symptomatic relief of benign prostatic hyperplasia </td></tr><tr><th>Pharmacodynamics</th><td>Silodosin is 583 times more selective for human alpha-1A receptors than alpha-1B receptors. It is also 56 times more selective for human alpha-1A receptors than alpha-1D. Silodosin does not prolong the QT interval. </td></tr><tr><th>Mechanism of action</th><td>Benign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH. 



</td></tr><tr><th>Absorption</th><td>Quickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose).
When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: 
Cmax = 61.6 &#177; 27.54 ng/mL;
Tmax = 2.6 &#177; 0.90 hours;  
AUC (0h-24h) = 373 ng&#8226;hr/ml. 
The AUC of its metabolite, KMD3213G, is four times greater than silodosin.  </td></tr><tr><th>Volume of distribution</th><td><p>49.5 L</p></td></tr><tr><th>Protein binding</th><td>97% bound to protein </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Extensively metabolized in the liver. The main metabolite is generated via glucuronidation (KMD-3213G) by UDP-2B7. Oxidation by alcohol and aldehyde dehydrogenases produces the second major metabolite, KMD-3293. KMD-3213G accumulates in the plasma as it is very hydrophilic. KMD-3213G is also an active metabolite in which it has 50% of silodosin's inhibitory activity. KMD-3293 is inactive.  Cytochrome P450 CYP 3A4 also generates some metabolites. </p></td></tr><tr><th>Route of elimination</th><td>Fecal (54.9%);  
Renal (33.5%) </td></tr><tr><th>Half life</th><td>Silodosin = 13.3 &#177; 8.07 hours;
KMD-3213G = 24 hours;  </td></tr><tr><th>Clearance</th><td><p>Plasma clearance = 10 L/h</p></td></tr><tr><th>Toxicity</th><td>Most common adverse reactions (incidence &gt; 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7383</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5847</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8467</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5833</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.7864</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7288</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8226</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6362</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6585</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7439</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7569</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5958</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5562</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7424</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5723</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6667
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8529
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4845 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.98
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8366
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>4 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>8 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Silodosin. Use of silodosin concomitantly with a strong CYP3A4 inhibitor is contraindicated. </td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Moderate inhibitors of CYP3A4 may increase levels of silodosin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects </td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of Silodosin. Increased Silodosin exposure may result in Silodosin toxicity. Concurrent use if not recommended. </td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy is not recommended.</td></tr><tr><td><a href="/drugs/DB01162">Terazosin</a></td><td>Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Silodosin, may occur. Monitor for hypotension during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism. Concomitant therapy is contraindicated. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin Cmax by approximately 18 &#8722; 43% and AUC by 4 &#8722; 49%</li></ul></td></tr></tbody></table>